REHOVOT, Israel, and HOBOKEN, N.J. — August 11, 2025 — Leads & Copy — Kamada Ltd. announced that the FDA has approved the supplement to its existing Biologics License Application (BLA) for Kamada Plasma’s collection center in Houston, TX, following an on-site inspection during the second quarter of this year. The center is now cleared to commence commercial sales of normal source plasma.
The 12,000 square foot Houston facility supports 50 donor beds, with a planned capacity of approximately 50,000 liters per year. The company anticipates it to be one of the largest collection centers for specialty plasma in the U.S.
Following FDA’s approval of the Houston location, Kamada intends to seek a subsequent inspection and approval by the European Medicines Agency (EMA) of this site.
Kamada’s CEO, Amir London, said that their three Texas-based sites, in Houston, San Antonio and Beaumont, provide them with significant capacity of specialty and normal source plasma collection.
In March 2025, Kamada announced the opening of its third center in San Antonio, TX. Each of the Houston and San-Antonio centers are expected to generate annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.
Contacts:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
